Cytotoxicities of bcr-abl b3a2-Specific CD4+ T-Cell Clones
| Clone . | Target . | HLA-DRB1 . | Peptide . | % Cytotoxicity* . |
|---|---|---|---|---|
| MY-1 | auto-LCL | 0901/1406 | None | 0.1 |
| b3a2 | 49.9 | |||
| allo-LCL #1 | 0901/0405 | None | −0.4 | |
| b3a2 | 49.4 | |||
| allo-LCL #2 | 0901/1406 | None | 0.8 | |
| b3a2 | 48.0 | |||
| allo-LCL #3 | 1406/1502 | None | −2.4 | |
| b3a2 | 0.2 | |||
| TO-1 | auto-LCL | 0901/0405 | None | 1.2 |
| b3a2 | 55.6 | |||
| allo-LCL #1 | 0901/1406 | None | 1.9 | |
| b3a2 | 56.9 | |||
| allo-LCL #2 | 0901/1406 | None | −0.2 | |
| b3a2 | 54.8 | |||
| allo-LCL #3 | 1406/1502 | None | −0.1 | |
| b3a2 | 2.0 |
| Clone . | Target . | HLA-DRB1 . | Peptide . | % Cytotoxicity* . |
|---|---|---|---|---|
| MY-1 | auto-LCL | 0901/1406 | None | 0.1 |
| b3a2 | 49.9 | |||
| allo-LCL #1 | 0901/0405 | None | −0.4 | |
| b3a2 | 49.4 | |||
| allo-LCL #2 | 0901/1406 | None | 0.8 | |
| b3a2 | 48.0 | |||
| allo-LCL #3 | 1406/1502 | None | −2.4 | |
| b3a2 | 0.2 | |||
| TO-1 | auto-LCL | 0901/0405 | None | 1.2 |
| b3a2 | 55.6 | |||
| allo-LCL #1 | 0901/1406 | None | 1.9 | |
| b3a2 | 56.9 | |||
| allo-LCL #2 | 0901/1406 | None | −0.2 | |
| b3a2 | 54.8 | |||
| allo-LCL #3 | 1406/1502 | None | −0.1 | |
| b3a2 | 2.0 |
Abbreviations: auto, autologous; allo, allogeneic.
The cytotoxicities of MY-1 and TO-1 to various target cells in the presence and absence of b3a2 synthetic peptide were determined by 4-hour 51Cr release assays at an effector:target ratio of 5:1.